Search Results - "Hendifar, A"

Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study by Tempero, M., Oh, D.-Y., Tabernero, J., Reni, M., Van Cutsem, E., Hendifar, A., Waldschmidt, D.-T., Starling, N., Bachet, J.-B., Chang, H.-M., Maurel, J., Garcia-Carbonero, R., Lonardi, S., Coussens, L.M., Fong, L., Tsao, L.C., Cole, G., James, D., Macarulla, T.

“…First-line treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) includes nab-paclitaxel/gemcitabine. Ibrutinib, a Bruton's tyrosine kinase…”
Get full text

Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer by Lurje, G., Zhang, W., Schultheis, A.M., Yang, D., Groshen, S., Hendifar, A.E., Husain, H., Gordon, M.A., Nagashima, F., Chang, H.M., Lenz, H.-J.

“…Identifying molecular markers for tumor recurrence is critical in successfully selecting patients with stage III colon cancer who are more likely to benefit…”
Get full text

Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study by Tempero, M., Oh, D., Macarulla, T., Reni, M., Van Cutsem, E., Hendifar, A., Waldschmidt, D., Starling, N., Bachet, J., Chang, H., Maurel, J., Lonardi, S., Coussens, L., Fong, L., Tsao, L., Cole, G., James, D., Tabernero, J.

Get full text

Health-related quality of life (HRQoL) in patients with early-stage pancreatic cancer (ESPC) receiving adjuvant or neoadjuvant chemotherapy (A/NAC): A systematic literature review (SLR) by Macarulla Mercade, T., Hendifar, A., Li, C.-P., Reni, M., Riess, H., Tempero, M.A., Dueck, A., Botteman, M.F., Deshpande, C., Lucas, E., Oh, D.-Y.

Get full text

RET rearrangements may arise following anti-EGFR therapy in advanced colorectal cancer by Rich, T A, Clifton, K, Grothey, A, Hendifar, A, Henry, D H, Kagawa, Y, Nakamura, Y, Okamoto, W, Tan, B R, Sherrill, G, Yoshino, T, Raymond, V M, Shiotsu, Y, Lanman, R B, Morris, V

Get full text

Impact of liver tumor burden on therapeutic effect of 177Lu-dotatate treatment in NETTER-1 study by Strosberg, J., Hendifar, A., Yao, J.C., Kulke, M., O’Dorisio, T., Caplin, M., Baum, R.P., Kunz, P., Hobday, T., Wolin, E., Mittra, E.S., Oberg, K., Ruszniewski, P., Polack, B., He, B., Barton, D., Santaro, P., Krenning, E.

Get full text

PD-006Final analysis of stage 1 data from a randomized phase 2 study of PEGPH20 plus nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients, utilizing Ventana companion diagnostic assay by Hingorani, S, Bullock, A, Harris, W, Wu, W, Jiang, P, Chondros, D, Khelifa, S, Aldrich, C, Pu, J, Hendifar, A

Get full text

HALO 109-301: Phase III, randomized, double-blind, placebo-controlled study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients with previously untreated hyaluronan (HA)-high stage IV pancreatic ductal adenocarcinoma (PDA) by Van Cutsem, E., Corrie, P.G., Ducreux, M.P., Sigal, D., Sahai, V., Oh, D.-Y., Bullock, A., Bang, Y.-J., Baron, A.D., Hendifar, A., Li, C.-P., Philip, P., Reni, M., Zalupski, M., Zheng, L., Berman, C., Chondros, D., Tempero, M.A.

Get full text

2321 High response rate and progression free survival with PEGylated recombinant human hyaluronidase added to Nab-Paclitaxel/ Gemcitabine in stage IV previously untreated pancreatic cancer patients with high-HA tumors: Interim results of a randomized Phase 2 study by Hingorani, S, Harris, W, Hendifar, A, Bullock, A, Wu, X, Huang, Y, Jiang, P, Hoff, D. Von

Get full text

SP-0570: Neuroendocrine tumours - personalised diagnosis and treatment using radiolabelled peptides by Baum, R.P, Strosberg, J, Wolin, E, Chasen, B, Kulke, M, Bushnell, D, Caplin, M, Hobday, T, Hendifar, A, Oberg, K, Lopera Sierra, M, Kwekkeboom, D, Ruszniewsk, P, Krenning, E, Mittra, E

Get full text

6LBA 177-Lu-Dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours: Results of the phase III NETTER-1 trial by Strosberg, J, Wolin, E, Chasen, B, Kulke, M, Bushnell, D, Caplin, M, Baum, R.P, Mittra, E, Hobday, T, Hendifar, A, Oberg, K, Lopera Sierra, M, Ruszniewski, P, Kwekkeboom, D

Get full text

Phase 3 Trial of Lu-177-Dotatate for Midgut Neuroendocrine Tumors by Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., Bushnell, D., O'Dorisio, T. M., Baum, R. P., Kulkarni, H. R., Caplin, M., Lebtahi, R., Hobday, T., Delpassand, E., Van Cutsem, E., Benson, A., Srirajaskanthan, R., Pavel, M., Mora, J., Berlin, J., Grande, E., Reed, N., Seregni, E., Öberg, Kjell, Sierra, M. Lopera, Santoro, P., Thevenet, T., Erion, J. L., Ruszniewski, P., Kwekkeboom, D., Krenning, E.

“…BACKGROUND Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited…”
Get full text

177 Lu-Dotatate améliore significativement la survie sans progression des patients atteints de tumeurs neuroendocrines métastatiques progressives de l’intestin moyen : résultats de l’essai de phase III NETTER-1 by Ruszniewski, P, Courbon, F, Lebtahi, R, Giammarile, F, Lombard-Bohas, C, Ansquer, C, Matysiac, T, Guimbaud, R, Taieb, D, Seitz, J.F, Ducreux, M, Baudin, E, Yao, J.C, Hendifar, A, Krenning, E, Strosber, J

“…NETTER-1 est une étude de phase III, multicentrique internationale, stratifiée, ouverte, randomisée, évaluant une radiothérapie interne vectorisée (RIV) par…”
Get full text

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors by Strosberg, Jonathan, El-Haddad, Ghassan, Wolin, Edward, Hendifar, Andrew, Yao, James, Chasen, Beth, Mittra, Erik, Kunz, Pamela L, Kulke, Matthew H, Jacene, Heather, Bushnell, David, O’Dorisio, Thomas M, Baum, Richard P, Kulkarni, Harshad R, Caplin, Martyn, Lebtahi, Rachida, Hobday, Timothy, Delpassand, Ebrahim, Van Cutsem, Eric, Benson, Al, Srirajaskanthan, Rajaventhan, Pavel, Marianne, Mora, Jaime, Berlin, Jordan, Grande, Enrique, Reed, Nicholas, Seregni, Ettore, Öberg, Kjell, Lopera Sierra, Maribel, Santoro, Paola, Thevenet, Thomas, Erion, Jack L, Ruszniewski, Philippe, Kwekkeboom, Dik, Krenning, Eric

“…In patients with midgut neuroendocrine tumors that progressed during octreotide analogue therapy, the addition of 177 Lu-Dotatate to octreotide resulted in an…”
Get full text

Impact of primary tumor resection on metastatic well-differentiated pancreatic neuroendocrine tumors by Russo, A., DiPeri, T., Tseng, J., Chen, C., Nissen, N., Amersi, F., Hendifar, A., Gangi, A.

Get full text

646P Phase Ib/II study of ompenaclid (RGX-202-01), afirst-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASm) second-line (2L) advanced/metastatic colorectal cancer (mCRC) by Hendifar, A., Spigel, D.R., Basu-Mallick, A., Richards, D., Fakih, M., Boles, J., Gupta, M., Chung, K., Cohn, A., Espinosa, A., Hourdequin, K.C., Johnson, K., Michalski, J.M., Misleh, J.G., Mukkamala, S., Paulson, A.S., Ratnam, S., Shao, S.H., Wasserman, R., Rosen, L.S.

Get full text

Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas by Gong, Jun, Yan, Jessica, Forscher, Charles, Hendifar, Andrew

“…Despite available therapies after initial systemic therapy, prognosis remains poor in relapsed or refractory soft tissue sarcomas (STS). The rational and…”
Get full text

PO-0813 A Phase I/II Study of durvalumab and stereotactic radiotherapy in locally advanced pancreatic cancer by Tuli, R., Nisen, N., Lo, S., Placencio, V., Gresham, G., Hendifar, A.

Get full text

P-125 Phase 1b study of RGX-202-01, a first-in-class oral inhibitor of the SLC6A8/CKB pathway, in combination with FOLFIRI and bevacizumab (BEV) in second-line advanced colorectal cancer (CRC) by Hendifar, A., Rosen, L., McRee, A., Cercek, A., Basu-Mallick, A., Spigel, D., Tavazoie, S., Rowinsky, E., Szarek, M., Gonsalves, F., Kurth, I., Andreu, C., Busby, R., Spector, S., Darst, D., Lebaka, N., Bechar, N., Tavazoie, M., Wasserman, R., Fakih, M.

Get full text

1555P Real-world treatment patterns and effectiveness of liposomal irinotecan in a NAPOLI1-based regimen among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): A multi-academic center chart review by Yu, K.H., Hendifar, A., Alese, O., Draper, A., Abdelrahim, M., Burns, E., Khan, G., Cockrum, P., Bhak, R., Nguyen, C., DerSarkissian, M., Duh, M.S., Bahary, N.

Get full text